Related Experiment Video

Updated: Aug 27, 2025

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

11.4K

Hyperglycemia and Lactic Acidosis Associated with Linezolid Therapy in an Extremely Premature Infant

Takafumi Asai1, Hiroki Kakita1,2, Nami Nakamura3

  • 1Department of Perinatal and Neonatal Medicine, Aichi Medical University, Nagakute, Japan.

Neonatology
|October 2, 2022
PubMed

Insights

Linezolid is generally safe for premature infants, but this case highlights potential risks. Monitoring glucose and lactate is crucial during linezolid therapy in extremely premature neonates.

Area of Science:

  • Neonatal Medicine
  • Pharmacology
  • Infectious Diseases

Background:

  • Linezolid is an antibiotic used for serious infections, including those caused by resistant bacteria.
  • Its safety profile in premature infants is generally considered favorable.
  • However, rare adverse events can occur, necessitating careful monitoring.

Observation:

  • A rare case involving an extremely premature infant (born at 24 weeks, 350g) is presented.
  • The infant received linezolid for a methicillin-resistant coagulase-negative Staphylococci infection.
  • Hyperglycemia and lactic acidosis developed after linezolid initiation.

Findings:

  • Serum lactate and glucose levels increased significantly during linezolid therapy.
  • These metabolic abnormalities resolved promptly after discontinuing linezolid.
  • This suggests a potential association between linezolid and these adverse events in extremely premature neonates.

Implications:

  • Clinicians should exercise caution when prescribing linezolid to extremely premature infants.
  • Close monitoring of glucose, lactate, and pH levels is crucial during linezolid treatment in this population.
  • Further research may be needed to understand the mechanisms and incidence of these adverse effects.

Keywords:
Extremely premature infantHyperglycemiaLactic acidosisLinezolid

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

1.9K
Intravenous Injections in Neonatal Mice05:17

Intravenous Injections in Neonatal Mice

Published on: November 11, 2014

59.3K

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
225
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
314
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
229
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
226
Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.0K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.6K